Saturday 17 October 2026 Export SIGA’s income statement to Excel — free account

Siga Technologies Inc.

SIGA Healthcare Drug Manufacturers Specialty & Generic

Siga Technologies Inc.’s revenue for fiscal 2025 (year ended December 2025) was $94.6 million, down 31.8% from fiscal 2024. In the quarter to June 2026, revenue fell 49.5%, EPS fell 66.0% and free cash flow fell 76.0%, each against the same quarter a year earlier. Dividend growth for five consecutive years.

3.17 0.02 −0.63%

Follow SIGA

Alert me

Market cap: $229.2M
P/E: 0.0×
Fwd P/E: 28.7×
Dividend yield: 0.00%
F-score: 5/9
Altman Z: 14.28
Beneish M: −4.02
Dividend safety: 36/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 42.68%

Capital & Financial Ratios $m

Market Cap 229.20

Revenue 53.66

Net Income (2.79)

Free Cash Flow (20.17)

Net Debt (117.58)

Current Ratio 21.72

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E 28.70

P/S ratio 4.24

P/B ratio 1.38

Past 5Y EPS Growth (14.73%)

This Y EPS Growth (18.29%)

Next Y EPS Growth 153.73%

Next Y revenue growth (36.71%)

Next 5Y EPS Growth 1.00%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 47.14%

10-year low 10-year high

P/B against its own 10 years 1.78%

10-year low 10-year high

EV/Sales against its own 10 years 51.14%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate 0.00

Annual Dividend Yield 0.00%

	total	individual payouts
2027	Powerpack
2026	0.60	0.60
2025	0.60	0.60
2023	0.00	0.45
2022	0.00	0.45
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack
2016	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	150	155	155	118
Receivables	21	21	3	7
Inventory	64	50	49	41
Other	—	—	—	—
	239	231	213	170

	2023	2024	2025	Q'26
Payables	1	1	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	54	25	18	8

Compound Annual Growth %

	10y	5y	3y
Sales	27.74%	(5.42%)	(5.13%)
Cash Flow	14.62%	(9.48%)	1.47%
Earnings	0.00%	(16.20%)	(11.78%)
Book Value	0.00%	8.90%	5.33%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	6	41	—	—	—
’25	7	81	3	4	95
’24	25	22	10	81	139
’23	8	6	9	116	140
’22	11	17	72	11	111
’21	5	9	5	115	134
’20	3	40	44	38	125

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	15	—	—	—
’25	7	63	(10)	(17)	43
’24	(6)	6	(7)	56	49
’23	24	(4)	(5)	79	95
’22	57	(2)	(5)	(8)	42
’21	(5)	(1)	2	16	11
’20	3	(9)	31	46	72

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	15	—	—	—
’25	7	63	(10)	(17)	43
’24	(6)	6	(7)	56	49
’23	24	(4)	(5)	79	95
’22	57	(2)	(5)	(8)	42
’21	(5)	(1)	2	16	11
’20	3	(9)	31	46	72

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.05)	0.17	—	—	—
’25	(0.01)	0.49	(0.09)	(0.08)	0.32
’24	0.14	0.03	0.02	0.63	0.82
’23	(0.01)	(0.04)	(0.01)	1.01	0.95
’22	0.00	0.03	0.45	(0.01)	0.46
’21	(0.01)	0.00	(0.04)	0.98	0.91
’20	(0.11)	0.26	0.31	0.26	0.71

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	0.35	2.80	4.21	4.28	3.96	5.66	5.84	4.22	4.26	4.95	Analyst estimates 2026–2028 Powerpack
	High	3.35	5.24	8.47	8.09	8.10	9.82	26.99	8.49	12.83	9.62
People
People	Employees	36	37	41	41	42	39	39	45	46	49
	Revenue/emp, $m	0.42	0.33	11.64	0.65	2.98	3.43	2.84	3.11	3.02	1.93
Income, $m
Income, $m	Revenue	15	12	477	27	125	134	111	140	139	95
	Gross margin, %	100.00	100.00	80.03	93.33	88.16	87.58	90.58	87.26	77.44	68.59
	EBT	(40)	(38)	412	(10)	74	89	44	88	76	30
	EBT margin, %	(264.78)	(312.41)	86.29	(38.06)	58.83	66.81	39.84	62.73	54.84	32.12
	Net income	(40)	(36)	422	(7)	56	69	34	68	59	23
	Depreciation	0	0	0	1	1	1	1	1	1	1
Per share, $
Per share, $	Revenue	0.26	0.16	5.97	0.33	1.58	1.77	1.52	1.96	1.95	1.32
	Earnings	(0.69)	(0.46)	5.28	(0.09)	0.71	0.92	0.46	0.95	0.83	0.33
	Cash flow	(2.04)	(0.23)	0.86	(0.22)	0.90	0.15	0.57	1.33	0.68	0.61
	Capex	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(2.04)	(0.23)	0.86	(0.22)	0.90	0.15	0.57	1.33	0.68	0.60
	Book value	(5.03)	(4.10)	1.29	1.21	1.64	2.31	2.33	2.76	3.03	2.78
	Shares, m	57	79	80	81	79	75	73	71	71	72
Valuation, ×
Valuation, ×	P/E	0.00	0.00	1.50	0.00	10.10	8.07	15.12	6.10	7.33	18.28
	P/S	11.18	30.86	1.32	14.45	4.61	4.24	4.63	2.97	3.09	4.62
	P/B	0.00	0.00	6.14	3.95	4.44	3.25	3.01	2.11	1.98	2.20
	EV/Sales	13.16	34.32	1.25	14.38	4.94	4.66	5.17	3.03	3.11	4.66
	EV/FCF	(1.69)	(22.76)	8.68	(21.09)	8.63	54.37	13.78	4.48	8.86	10.23
Cash, $m
Cash, $m	Operating cash flow	(117)	(18)	69	(18)	72	11	42	95	49	43
	Capex	0	0	0	0	0	0	—	0	0	0
	Free cash flow	(117)	(18)	69	(18)	72	11	42	95	49	43
Balance, $m
Balance, $m	Working capital	62	31	110	88	133	178	164	185	206	195
	Total debt	67	71	76	80	2	3	2	—	—	—
	Net debt	28	40	(37)	(81)	(118)	(103)	(99)	(150)	(155)	(155)
	Shareholders’ equity	(287)	(323)	103	98	130	174	170	197	216	199
Returns, %
Returns, %	ROA	(22.90)	(23.71)	242.34	(3.60)	32.34	38.10	16.55	30.29	23.75	10.04
	ROIC	0.00	0.00	334.46	(8.62)	443.69	78.23	37.39	111.88	72.41	33.78
	ROE	13.88	11.87	(383.07)	(7.22)	49.51	45.68	19.68	37.09	28.70	11.23

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CGC Canopy Growth Corporation	$311.2M	— (loss-making)	— (loss-making)	+12.41% (above 0%: growing)	n/m	−117.60% (below 0%: shrinking)	27.40%	(27.24%)	Compare
ANIK Anika Therapeutics Inc.	$276.9M	— (loss-making)	— (loss-making)	+15.56% (above 0%: growing)	n/m	+61.58% (above 0%: growing)	65.15%	9.06%	Compare
ACB Aurora Cannabis Inc.	$265.8M	— (loss-making)	— (loss-making)	−31.15% (below 0%: shrinking)	n/m	−293.56% (below 0%: shrinking)	52.73%	(12.92%)	Compare
BIOA BioAge Labs, Inc.	$245.6M	— (loss-making)	— (loss-making)	+1.62% (above 0%: growing)	n/m	+2.68% (above 0%: growing)	100.00%	(1,196.78%)	Compare
LFCR Lifecore Biomedical, Inc.	$244.1M	— (loss-making)	— (loss-making)	−6.25% (below 0%: shrinking)	n/m	−117.03% (below 0%: shrinking)	35.34%	7.51%	Compare
SIGA Siga Technologies Inc.	$229.2M	— (loss-making)	28.7×	−49.45% (below 0%: shrinking)	−66.00% (below 0%: shrinking)	−75.95% (below 0%: shrinking)	57.17%	33.91%
AKBA Akebia Therapeutics, Inc.	$192.7M	— (loss-making)	— (loss-making)	−21.36% (below 0%: shrinking)	n/m	−88.99% (below 0%: shrinking)	78.78%	(12.88%)	Compare
DERM Journey Medical Corporation	$144.7M	— (loss-making)	91.8×	+23.33% (above 0%: growing)	n/m	−84.08% (below 0%: shrinking)	66.81%	2.46%	Compare
ORGO Organogenesis	$142.8M	— (loss-making)	— (loss-making)	−56.68% (below 0%: shrinking)	n/m	+10.29% (above 0%: growing)	45.90%	(116.54%)	Compare
Median of peers	$244.8M	—	—	−2.31%	—	−86.54%	58.94%	(12.90%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Siga Technologies Inc. (SIGA) key facts

Concern: Siga Technologies Inc.’s revenue for fiscal 2025 (year ended December 2025) was $94.6 million, down 31.8% from fiscal 2024.
Siga Technologies Inc. (SIGA) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, SIGA traded at $3.17, a market capitalization of $229.2 million.
Return on equity was 11.2% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 14.28 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.